Gober Leah, Bui Allen, Ruddy Jean Marie
School of Medicine, Mercer University School of Medicine, USA.
Division of Vascular Surgery, University of South Carolina, USA.
Ann Vasc Med Res. 2020;7(4). Epub 2020 Jul 15.
Best medical therapy for peripheral artery disease (PAD) includes statin and anti-platelet agents, a combination shown to decrease rates of major cardiovascular events. Despite these findings, many patients remain undertreated and the objective of this project was to investigate the rate of initiating anti-platelet and statin therapy for inpatients newly diagnosed with PAD with a focus on disparities by race and sex. A retrospective chart review of inpatients with newly diagnosed PAD was performed between January 1, 2016 to December 31, 2016 at a single institution. Demographics and comorbid conditions were collected. Primary outcomes included antiplatelet and statin prescription at discharge. The 44 patients included in this study were predominantly male (59% vs. 41%) and African American (61% vs. 39%). Between admission and discharge, prescriptions rose from 70% to 82% for statin and 82% to 91% for anti-platelet agents. Vascular specialists were more successful than non-vascular specialists at initiating medical therapy, with statin prescriptions increasing 22% and anti-platelet prescriptions climbing 23% for those admitted to a vascular specialist. Interestingly, when the ABI was reported in the normal range, rates of statin initiation were particularly compromised at only 40%. For the total patient sample, those discharged without a statin were more commonly African American (63%) and the majority were female (67%). All patients discharged without an antiplatelet were African American and 50% were females. Despite national guidelines, patients with PAD continue to be discharged without optimal medical therapy. This study suggests that obstacles to initiation may include race, sex, admitting service, or presence of a normal ABI. Further investigation is warranted to determine effective avenues for provider education and system-wide initiatives.
外周动脉疾病(PAD)的最佳药物治疗包括他汀类药物和抗血小板药物,这两种药物联合使用可降低主要心血管事件的发生率。尽管有这些研究结果,但许多患者仍未得到充分治疗,本项目的目的是调查新诊断为PAD的住院患者开始使用抗血小板和他汀类药物治疗的比例,并重点关注种族和性别的差异。2016年1月1日至2016年12月31日期间,在一家机构对新诊断为PAD的住院患者进行了回顾性病历审查。收集了人口统计学和合并症信息。主要结局包括出院时的抗血小板和他汀类药物处方。本研究纳入的44例患者中男性占主导(59%对41%),非裔美国人占主导(61%对39%)。在入院和出院之间,他汀类药物的处方率从70%升至82%,抗血小板药物的处方率从82%升至91%。血管专科医生在启动药物治疗方面比非血管专科医生更成功,对于入住血管专科医生处的患者,他汀类药物处方增加了22%,抗血小板药物处方增加了23%。有趣的是,当踝臂指数(ABI)报告在正常范围内时,他汀类药物起始率特别低,仅为40%。在全部患者样本中,未使用他汀类药物出院的患者更常见于非裔美国人(63%),且大多数为女性(67%)。所有未使用抗血小板药物出院的患者均为非裔美国人,50%为女性。尽管有国家指南,但PAD患者出院时仍未接受最佳药物治疗。本研究表明,起始治疗的障碍可能包括种族、性别、收治科室或ABI正常。有必要进一步调查以确定对医疗服务提供者进行教育的有效途径和全系统的举措。